Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration

Science Signaling

Volumn 7, Issue 355, 2014, Pages

  Haskins, Jonathan W ^a   Nguyen, Don X ^a   Stern, David F ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; HIPPO PROTEIN; LAPATINIB; LYSOPHOSPHATIDIC ACID; MEVALONIC ACID; NEU DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR YAP1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CTGF PROTEIN, HUMAN; ERBB4 PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; NRG1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; TRANSCRIPTION FACTOR; YY1AP1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; GENE CONTROL; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MECHANOTRANSDUCTION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CONNECTIVE TISSUE GROWTH FACTOR; ERLOTINIB HYDROCHLORIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MECHANOTRANSDUCTION, CELLULAR; NEUREGULIN-1; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RECEPTOR, ERBB-4; TRANSCRIPTION FACTORS;

EID: 84916628454     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005770     Document Type: Article

References (62)

1. T. T. Junttila, M. Sundvall, J. A. Määttä, K. Elenius, Erbb4 and its isoforms: Selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc. Med. 10, 304-310 (2000).
2. A. Buonanno, G. D. Fischbach, Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr. Opin. Neurobiol. 11, 287-296 (2001).
3. H. Tidcombe, A. Jackson-Fisher, K. Mathers, D. F. Stern, M. Gassmann, J. P. Golding, Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc. Natl. Acad. Sci. U.S.A. 100, 8281-8286 (2003).
4. F. E. Jones, T. Welte, X. Y. Fu, D. F. Stern, ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell Biol. 147, 77-88 (1999).
5. C. Y. Ni, M. P. Murphy, T. E. Golde, G. Carpenter, g-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294, 2179-2181 (2001).
6. G. A. Vidal, A. Naresh, L. Marrero, F. E. Jones, Presenilin-dependent g-secretase processing regulates multiple ERBB4/HER4 activities. J. Biol. Chem. 280, 19777-19783 (2005).
7. J. Schlessinger, M. A. Lemmon, Nuclear signaling by receptor tyrosine kinases: The first robin of spring. Cell 127, 45-48 (2006).
8. M. Gilmore-Hebert, R. Ramabhadran, D. F. Stern, Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways. Mol. Cancer Res. 8, 1388-1398 (2010).
9. S. P. Sardi, J. Murtie, S. Koirala, B. A. Patten, G. Corfas, Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 127, 185-197 (2006).
10. Y. Zhu, L. L. Sullivan, S. S. Nair, C. C. Williams, A. K. Pandey, L. Marrero, R. K. Vadlamudi, F. E. Jones, Coregulation of estrogen receptor by ERBB4/HER4 establishes a growthpromoting autocrine signal in breast tumor cells. Cancer Res. 66, 7991-7998 (2006).
11. C. C. Williams, J. G. Allison, G. A. Vidal, M. E. Burow, B. S. Beckman, L. Marrero, F. E. Jones, The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J. Cell Biol. 167, 469-478 (2004).
12. M. Sundvall, V. Veikkolainen, K. Kurppa, Z. Salah, D. Tvorogov, E. J. van Zoelen, R. Aqeilan, K. Elenius, Cell death or survival promoted by alternative isoforms of ErbB4. Mol. Biol. Cell 21, 4275-4286 (2010).
13. V. Veikkolainen, K. Vaparanta, K. Halkilahti, K. Iljin, M. Sundvall, K. Elenius, Function of ERBB4 is determined by alternative splicing. Cell Cycle 10, 2647-2657 (2011).
14. M. Sundvall, K. Iljin, S. Kilpinen, H. Sara, O. P. Kallioniemi, K. Elenius, Role of ErbB4 in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 259-268 (2008).
15. R. S. Muraoka-Cook, M. A. Sandahl, K. E. Strunk, L. C. Miraglia, C. Husted, D. M. Hunter, K. Elenius, L. A. Chodosh, H. S. Earp III, ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol. Cell. Biol. 29, 4935-4948 (2009).
16. R. S. Muraoka-Cook, M. Sandahl, C. Husted, D. Hunter, L. Miraglia, S. M. Feng, K. Elenius, H. S. Earp III, The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol. Biol. Cell 17, 4118-4129 (2006).
17. H. J. Lee, K. M. Jung, Y. Z. Huang, L. B. Bennett, J. S. Lee, L. Mei, T. W. Kim, Presenilindependent g-secretase-like intramembrane cleavage of ErbB4. J. Biol. Chem. 277, 6318-6323 (2002).
18. C. Kandoth, M. D. McLellan, F. Vandin, K. Ye, B. Niu, C. Lu, M. Xie, Q. Zhang, J. F. McMichael, M. A. Wyczalkowski, M. D. Leiserson, C. A. Miller, J. S. Welch, M. J. Walter, M. C.Wendl, T. J. Ley, R. K. Wilson, B. J. Raphael, L. Ding, Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
19. R. Srinivasan, C. E. Gillett, D. M. Barnes,W. J. Gullick, Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 60, 1483-1487 (2000).
20. T. T. Junttila, M. Sundvall, M. Lundin, J. Lundin, M. Tanner, P. Härkönen, H. Joensuu, J. Isola, K. Elenius, Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 65, 1384-1393 (2005).
21. R. Srinivasan, R. Poulsom, H. C. Hurst, W. J. Gullick, Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 185, 236-245 (1998).
22. A. D. Thor, S. M. Edgerton, F. E. Jones, Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am. J. Pathol. 175, 1802-1809 (2009).
23. D. M. Abd El-Rehim, S. E. Pinder, C. E. Paish, J. A. Bell, R. S. Rampaul, R. W. Blamey, J. F. Robertson, R. I. Nicholson, I. O. Ellis, Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer 91, 1532-1542 (2004).
24. C. K. Tang, X. Z. Concepcion, M. Milan, X. Gong, E. Montgomery, M. E. Lippman, Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. 59, 5315-5322 (1999).
25. A. J. Lodge, J. J. Anderson, W. J. Gullick, B. Haugk, R. C. Leonard, B. Angus, Type 1 growth factor receptor expression in node positive breast cancer: Adverse prognostic significance of c-erbB-4. J. Clin. Pathol. 56, 300-304 (2003).
26. I. Bièche, P. Onody, S. Tozlu, K. Driouch, M. Vidaud, R. Lidereau, Prognostic value of ERBB family mRNA expression in breast carcinomas. Int. J. Cancer 106, 758-765 (2003).
27. T. D. Prickett, N. S. Agrawal, X. Wei, K. E. Yates, J. C. Lin, J. R. Wunderlich, J. C. Cronin, P. Cruz, S. A. Rosenberg, Y. Samuels, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127-1132 (2009).
28. V. B. Wali, J. W. Haskins, M. Gilmore-Hebert, J. T. Platt, Z. Liu, D. F. Stern, Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells. Mol. Cancer Res. 12, 1140-1155 (2014).
29. D. N. Amin, A. S. Perkins, D. F. Stern, Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 23, 1428-1438 (2004).
30. J. Dong, G. Feldmann, J. Huang, S. Wu, N. Zhang, S. A. Comerford, M. F. Gayyed, R. A. Anders, A. Maitra, D. Pan, Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133 (2007).
31. M. Overholtzer, J. Zhang, G. A. Smolen, B. Muir, W. Li, D. C. Sgroi, C. X. Deng, J. S. Brugge, D. A. Haber, Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. U.S.A. 103, 12405-12410 (2006).
32. L. Zender, M. S. Spector, W. Xue, P. Flemming, C. Cordon-Cardo, J. Silke, S. T. Fan, J. M. Luk, M. Wigler, G. J. Hannon, D. Mu, R. Lucito, S. Powers, S. W. Lowe, Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253-1267 (2006).
33. B. Zhao, X.Wei,W. Li, R.S. Udan, Q. Yang, J.Kim, J. Xie,T. Ikenoue, J. Yu, L. Li, P. Zheng, K. Ye, A. Chinnaiyan, G. Halder, Z. C. Lai, K. L. Guan, Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007).
34. B. Zhao, L. Li, Q. Lei, K. L. Guan, The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev. 24, 862-874 (2010).
35. N. Zhang, H. Bai, K. K. David, J. Dong, Y. Zheng, J. Cai,M. Giovannini, P. Liu, R. A. Anders, D. Pan, The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27-38 (2010).
36. S. Dupont, L. Morsut, M. Aragona, E. Enzo, S. Giulitti, M. Cordenonsi, F. Zanconato, J. Le Digabel, M. Forcato, S. Bicciato, N. Elvassore, S. Piccolo, Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183 (2011).
37. G. Halder, S. Dupont, S. Piccolo, Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 13, 591-600 (2012).
38. F. X. Yu, B. Zhao, N. Panupinthu, J. L. Jewell, I. Lian, L. H. Wang, J. Zhao, H. Yuan, K. Tumaneng, H. Li, X. D. Fu, G. B. Mills, K. L. Guan, Regulation of the Hippo-YAP pathway by G-protein coupled receptor signaling. Cell 150, 780-791 (2012).
39. G. Sorrentino, N. Ruggeri, V. Specchia, M. Cordenonsi, M. Mano, S. Dupont, A. Manfrin, E. Ingallina, R. Sommaggio, S. Piazza, A. Rosato, S. Piccolo, G. Del Sal, Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 16, 357-366 (2014).
40. B. V. Reddy, K. D. Irvine, Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev. Cell 24, 459-471 (2013).
41. R. Fan, N. G. Kim, B. M. Gumbiner, Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl. Acad. Sci. U.S.A. 110, 2569-2574 (2013).
42. J. Zhang, J. Y. Ji, M. Yu, M. Overholtzer, G. A. Smolen, R.Wang, J. S. Brugge, N. J. Dyson, D. A. Haber, YAP-dependent induction of amphiregulin identifies a non-cell-Autonomous component of the Hippo pathway. Nat. Cell Biol. 11, 1444-1450 (2009).
43. A. Komuro, M. Nagai, N. E. Navin, M. Sudol, WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxylterminal fragment of ErbB-4 that translocates to the nucleus. J. Biol. Chem. 278, 33334-33341 (2003).
44. J. Omerovic, E. M. Puggioni, S. Napoletano, V. Visco, R. Fraioli, L. Frati, A. Gulino, M. Alimandi, Ligand-regulated association of ErbB-4 to the transcriptional co-Activator YAP65 controls transcription at the nuclear level. Exp. Cell Res. 294, 469-479 (2004).
45. K. Hoeing, K. Zscheppang,S. Mujahid, S. Murray, M. V.Volpe, C. E. Dammann, H. C. Nielsen, Presenilin-1 processing of ErbB4 in fetal type II cells is necessary for control of fetal lung maturation. Biochim. Biophys. Acta 1813, 480-491 (2011).
46. M. Cordenonsi, F. Zanconato, L. Azzolin, M. Forcato, A. Rosato, C. Frasson, M. Inui, M. Montagner, A. R. Parenti, A. Poletti, M. G. Daidone, S. Dupont, G. Basso, S. Bicciato, S. Piccolo, The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772 (2011).
47. Y. Bao, K. Nakagawa, Z. Yang, M. Ikeda, K. Withanage, M. Ishigami-Yuasa, Y. Okuno, S. Hata, H. Nishina, Y. Hata, A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J. Biochem. 150, 199-208 (2011).
48. S. Basu, N. F. Totty, M. S. Irwin, M. Sudol, J. Downward, Akt phosphorylates the Yesassociated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73- mediated apoptosis. Mol. Cell 11, 11-23 (2003).
49. T. Adilakshmi, J. Ness-Myers, C. Madrid-Aliste, A. Fiser, N. Tapinos, A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination. J. Neurosci. 31, 5106-5119 (2011).
50. X. Feng, M. S. Degese, R. Iglesias-Bartolome, J. P. Vaque, A. A. Molinolo, M. Rodrigues, M. R. Zaidi, B. R. Ksander, G. Merlino, A. Sodhi, Q. Chen, J. S. Gutkind, Hippoindependent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated Rho GTPase signaling circuitry. Cancer Cell 25, 831-845 (2014).
51. F. X. Yu, J. Luo, J. S. Mo, G. Liu, Y. C. Kim, Z. Meng, L. Zhao, G. Peyman, H. Ouyang, W. Jiang, J. Zhao, X. Chen, L. Zhang, C. Y. Wang, B. C. Bastian, K. Zhang, K. L. Guan, Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25, 822-830 (2014).
52. K. F. Harvey, X. Zhang, D. M. Thomas, The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257 (2013).
53. Q. Chen, N. Zhang, R. S. Gray, H. Li, A. J. Ewald, C. A. Zahnow, D. Pan, A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 28, 432-437 (2014).
54. A. Skibinski, J. L. Breindel, A. Prat, P. Galván, E. Smith, A. Rolfs, P. B. Gupta, J. Labaer, C. Kuperwasser, The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 6, 1059-1072 (2014).
55. W. Long, K. U. Wagner, K. C. Lloyd, N. Binart, J.M. Shillingford, L. Hennighausen, F. E. Jones, Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 130, 5257-5268 (2003).
56. M. Prager-Khoutorsky, A. Lichtenstein, R. Krishnan, K. Rajendran, A. Mayo, Z. Kam, B. Geiger, A. D. Bershadsky, Fibroblast polarization is a matrix-rigidity-dependent process controlled by focal adhesion mechanosensing. Nat. Cell Biol. 13, 1457-1465 (2011).
57. B. C. Low, C. Q. Pan, G. V. Shivashankar, A. Bershadsky, M. Sudol, M. Sheetz, YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 588, 2663-2670 (2014).
58. M. Aragona, T. Panciera, A. Manfrin, S. Giulitti, F. Michielin, N. Elvassore, S. Dupont, S. Piccolo, A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154, 1047-1059 (2013).
59. K. L. Meerbrey, G. Hu, J. D. Kessler, K. Roarty, M. Z. Li, J. E. Fang, J. I. Herschkowitz, A. E. Burrows,A. Ciccia, T. Sun, E. M. Schmitt, R. J. Bernardi,X. Fu, C. S. Bland, T. A. Cooper, R. Schiff, J. M. Rosen, T. F. Westbrook, S. J. Elledge, The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 108, 3665-3670 (2011).
60. J. M. Lamar, P. Stern, H. Liu, J. W. Schindler, Z. G. Jiang, R. O. Hynes, The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc. Natl. Acad. Sci. U.S.A. 109, E2441-E2450 (2012).
61. J. Zhang, G. A. Smolen, D. A. Haber, Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res. 68, 2789-2794 (2008).
62. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).